drugset / Trial / NCT01353755
2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate efficacy and tolerability of specific subcutaneous immunotherapy with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense) in subjects with rhinoconjunctivitis caused by grass pollen with/without controlled asthma.
Timeline
- Start
- 2009-10
- Primary completion
- 2012-08
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rPhleum | Protein / enzyme biologic | 0.78 ug/ml | Subcutaneous |
| Subject | rPhleum | Protein / enzyme biologic | 6.25 ug/ml | Subcutaneous |
| Subject | rPhleum | Protein / enzyme biologic | 50 ug/ml | Subcutaneous |
| Subject | rPhleum | Protein / enzyme biologic | 200 ug/ml | Subcutaneous |